EquityZen Growth Technology Fund LLC - Series 2294
Raised
$181K
Investors
—
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2294 is a private equity vehicle filed on June 16, 2026, claiming exemptions under Rules 506(b), 506(c), 504, and 4(a)(5). The filing is in pre-open status with no capital raised, investor count, or minimum investment disclosed. This entity is part of the EquityZen platform, which operates 168 related EDGAR-registered series funds targeting private growth-stage technology companies.
This filing represents a typical series vehicle within EquityZen's multi-SPV platform model for accessing pre-IPO technology equity. The use of multiple exemptions (506(b), 506(c), 504, and 4(a)(5)) in combination is relatively uncommon and suggests flexibility for both accredited and potentially non-accredited investors across different distribution channels. Historical EquityZen series have raised between $145K and $857K, indicating deal-specific capitalization rather than pooled fund structures.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govIs this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
